Transitioning a Phase III Age-related Macular Degeneration Clinical Trial
UBC is currently managing a phase III ophthalmology clinical trial for the treatment of patients with age-related macular degeneration. This safety and efficacy study investigates a new dosing schedule for a product that is currently commercially approved for a different dosing regimen. This study is being conducted at 70 sites across the US with a target population of at least 500 patients 60 years of age and older.
UBC has proven processes for initiating and growing relationships with clinical trial sites. UBC also prioritizes engaging and involving patients in research. This research sponsor trusted UBC to transition an active study and improve trial site experience and engagement while also maximizing the collection of quality data.
Download this case study to see how UBC managed the needs of ophthalmology sites and patients in order to successfully transition a phase III clinical trial and meet submission deadlines.
To learn more about UBC’s approach and work with clinical trial management and late stage research, click here.